# ⬇️ Orthostatic Hypotension

## 🔄 The Orthostatic Paradox

**Class 1 Recommendation:** Improved blood pressure control *reduces* orthostatic hypotension risk through better autonomic function and reduced arterial stiffness. The key is balancing intensive treatment benefits with individual tolerance.

### 📏 Definition and Diagnostic Criteria

#### 🔢 Quantitative Definition

- **Systolic:** ≥20 mmHg decrease
- **Diastolic:** ≥10 mmHg decrease
- **Timing:** Within 3 minutes of standing
- **HR Response:** ≥30 bpm increase (POTS)

#### 🔍 Clinical Assessment

- **Symptoms:** Dizziness, lightheadedness, falls
- **Timing:** Morning vs. postprandial
- **Triggers:** Heat, exercise, medications
- **Duration:** Immediate vs. delayed recovery

#### ⚡ Special Considerations

- **Masked OH:** No symptoms despite BP drop
- **Supine HTN:** Concurrent condition
- **Pseudohypertension:** In elderly patients
- **White-coat effect:** Office vs. home readings

### 📐 Standardized Measurement Protocol

##### 1️⃣ Supine Position

Patient lies flat for 5 minutes minimum. Record BP and HR at baseline.

##### 2️⃣ Active Standing

Patient stands up actively (not assisted). Begin timing immediately.

##### 3️⃣ 1-Minute Reading

Record BP and HR at 1 minute post-standing. Note any symptoms.

##### 4️⃣ 3-Minute Reading

Final measurement at 3 minutes. Calculate changes from baseline.

##### 5️⃣ Symptom Assessment

Document dizziness, weakness, falls risk throughout procedure.

##### 6️⃣ Recovery Monitoring

Observe return to baseline and symptom resolution.

### 👴 Age-Related Mechanisms

#### Physiologic Changes

- **Arterial stiffness:** Reduced vascular compliance
- **Baroreceptor sensitivity:** 50% reduction by age 70
- **Cardiac output:** Decreased stroke volume response
- **Renal function:** Impaired sodium retention

#### Clinical Implications

- Higher baseline prevalence in elderly (30%)
- Greater susceptibility to antihypertensive effects
- Increased fall risk and fracture complications
- Need for more gradual BP reduction strategies

### 💊 Medication-Induced OH

#### High-Risk Medications

- **Alpha-blockers:** Highest risk, especially doxazosin
- **Diuretics:** Volume depletion, especially loops
- **Vasodilators:** Direct smooth muscle relaxation
- **Nitrates:** Venous pooling, reduced preload

#### Risk Mitigation Strategies

- Start low, go slow titration approach
- Evening dosing for long-acting agents
- Combination therapy over high-dose monotherapy
- Patient education on position changes

### 💧 Volume-Related Factors

#### Intravascular Volume

- **Dehydration:** Acute illness, poor intake
- **Blood loss:** Occult GI bleeding common
- **Renal losses:** Diabetes, diuretic excess
- **Third-spacing:** Heart failure, liver disease

#### Assessment and Management

- Fluid balance evaluation and optimization
- Electrolyte monitoring, especially sodium
- Diuretic dose adjustment or timing changes
- Compression stockings for venous pooling

### 🧠 Neurogenic Causes

#### Autonomic Dysfunction

- **Diabetes:** Diabetic autonomic neuropathy
- **Parkinson disease:** α-synuclein deposition
- **Multiple sclerosis:** Demyelination effects
- **Pure autonomic failure:** Rare primary condition

#### Diagnostic Considerations

- Heart rate variability testing
- Tilt table testing if indicated
- Norepinephrine levels (supine vs. standing)
- Evaluation for underlying neurologic disease

### 🔬 2025 Guideline Evidence Base

#### ✅ Class 1 Recommendation

**Improved BP control reduces OH risk** through better autonomic function and reduced arterial stiffness. This counterintuitive finding supports continued antihypertensive therapy in most patients.

#### ⚠️ Class 2a Recommendation

**Against withholding intensive treatment** for asymptomatic orthostatic hypotension. Cardiovascular benefits outweigh theoretical risks in absence of symptoms or falls.

#### 🎯 Clinical Application

Focus on **symptomatic OH and falls risk** rather than absolute BP numbers. Individual assessment of tolerance and quality of life impacts guides management decisions.

### 📊 SPRINT Trial OH Analysis

#### Trial Design

- **Population:** 9,361 high-risk patients
- **Comparison:** Intensive (\<120) vs. standard (\<140)
- **Follow-up:** 3.26 years median
- **OH Assessment:** Standing BP measured

#### OH Findings

- **Prevalence:** 23% baseline, similar both groups
- **Incident OH:** No difference intensive vs. standard
- **Falls:** No increased risk with intensive treatment
- **Syncope:** Rare in both groups (0.7% vs. 0.5%)

#### Clinical Implications

- **Safety:** Intensive treatment well-tolerated
- **Benefits:** 25% ↓ CV events, 27% ↓ mortality
- **Quality of life:** No significant impairment
- **Patient selection:** Exclude frail elderly

### 🧮 Orthostatic Hypotension Risk Calculator

#### Patient Characteristics

Age Baseline Systolic BP Standing Systolic BP Risk Factors Symptomatic (dizziness, falls) Diabetes Parkinson Disease Alpha-blocker Use High-dose Diuretics Dehydration/Volume Loss

#### Risk Assessment

### ⚕️ Evidence-Based Management Strategy Matrix

| Patient Category | OH Status | BP Target | Treatment Approach | Monitoring Frequency | Special Considerations |
|----|----|----|----|----|----|
| **Young (\<65 years)** | Asymptomatic OH | \<130/80 mmHg | Continue intensive treatment | Standard (3-6 months) | Educate on position changes |
| **Middle-aged (65-75)** | Asymptomatic OH | \<130/80 mmHg | Gradual BP reduction | Monthly until stable | Home BP monitoring |
| **Elderly (75-85)** | Mild symptoms | \<140/90 → \<130/80 | Stepwise approach | Bi-weekly initially | Falls risk assessment |
| **Very elderly (\>85)** | Symptomatic OH | \<140/90 mmHg | Conservative management | Weekly until stable | Quality of life focus |
| **Frail/Limited mobility** | Severe symptoms | \<150/90 mmHg | Medication reduction | Weekly monitoring | Multidisciplinary care |
| **High CV risk** | Any OH | \<130/80 mmHg | Benefits outweigh risks | Standard monitoring | Cardio-protective priority |
| **Neurogenic OH** | Severe OH | Individualized | Specialist management | Continuous monitoring | Fludrocortisone, midodrine |

### 🏃‍♂️ Behavioral Interventions

#### Position Change Techniques

- **Gradual standing:** 30-second stages, sit → stand
- **Leg exercises:** Calf pumps before standing
- **Physical counter-maneuvers:** Leg crossing, squatting
- **Morning preparation:** Head elevation, slow movements

#### Lifestyle Modifications

- Adequate hydration (2-3L daily unless contraindicated)
- Increased sodium intake (unless heart failure)
- Small, frequent meals to avoid postprandial OH
- Compression stockings (20-30 mmHg)
- Physical conditioning and resistance training

### 💊 Pharmacologic Strategies

#### Medication Optimization

- **Dosing timing:** Evening dosing for long-acting agents
- **Formulation changes:** Extended-release preferred
- **Drug selection:** Avoid alpha-blockers, high-dose diuretics
- **Combination therapy:** Lower doses, complementary mechanisms

#### Orthostatic Hypotension Treatments

- **Fludrocortisone:** 0.1-0.2mg daily, monitor K+ and edema
- **Midodrine:** 2.5-10mg TID, avoid evening dose
- **Droxidopa:** 100-600mg TID for neurogenic OH
- **Pyridostigmine:** 60mg TID for autonomic dysfunction

### 🔧 Device and Physical Therapies

#### Compression Devices

- **Graduated stockings:** 20-30 mmHg compression
- **Abdominal binders:** Reduce splanchnic pooling
- **Pneumatic devices:** Intermittent compression
- **Whole-body suits:** Severe refractory cases

#### Advanced Interventions

- Head-up tilt sleeping (4-6 inches)
- Targeted exercise training programs
- Biofeedback and autonomic training
- Electrical stimulation devices (experimental)

### 📋 Clinical Case: Balancing Intensive BP Control with OH Risk

#### Patient Presentation

**Demographics:** 72-year-old male

**Medical History:** Type 2 DM, CAD s/p CABG, CKD stage 3

**Current BP:** 165/95 mmHg (office), 155/90 mmHg (home)

**PREVENT Risk:** 22% (high risk)

**Standing BP:** 140/85 mmHg (25 mmHg drop)

**Symptoms:** Mild morning dizziness, no falls

#### Current Medications

- Lisinopril 20mg daily
- Amlodipine 5mg daily
- Hydrochlorothiazide 25mg daily
- Metoprolol XL 50mg daily

#### Management Strategy

**Decision:** Continue intensive BP treatment given high cardiovascular risk and minimal symptoms despite orthostatic changes.

##### Optimization Plan:

- Switch HCTZ to chlorthalidone 25mg daily
- Move amlodipine to evening dosing
- Add patient education on position changes
- Home BP monitoring with standing measurements
- Compression stockings trial

##### Monitoring Protocol:

- 2-week follow-up: symptom assessment, standing BP
- 4-week follow-up: home BP log review, medication adjustment
- 8-week follow-up: target BP achievement, falls assessment
- Goal: \<130/80 mmHg (2025 AHA/ACC, ADA Standards of Care) without symptomatic OH
- Both guidelines, and why the lower one is not pursued here: KDIGO 2021 (Blood Pressure in CKD) suggests systolic \<120 mmHg *when tolerated*, on standardized office measurement (grade 2B, driven by the CKD subgroup of SPRINT), and excludes transplant and dialysis patients. This patient has CKD stage 3, so KDIGO applies — but his 25 mmHg orthostatic drop with symptoms is precisely the "when tolerated" limit, so \<130/80 without symptomatic OH is the operative goal. Note also that KDIGO's number presumes a standardized or unattended reading, which a routine clinic cuff does not meet.

### 📅 OH Monitoring and Management Timeline

1

#### Baseline Assessment (Week 0)

Comprehensive OH evaluation with standardized measurements, symptom assessment, falls risk screening, and medication review. Establish individual tolerance baseline.

2

#### Early Intervention (Weeks 1-2)

Implement behavioral modifications, adjust medication timing, begin compression therapy. Patient education on recognition and management of symptoms.

3

#### Close Monitoring Phase (Weeks 2-8)

Bi-weekly assessments with home BP monitoring including standing measurements. Medication titration based on tolerance and BP control. Falls diary implementation.

4

#### Stabilization Phase (Months 2-6)

Monthly monitoring with focus on sustained BP control and symptom stability. Quality of life assessment and functional capacity evaluation.

5

#### Long-term Management (6+ months)

Quarterly assessments with annual comprehensive OH evaluation. Medication optimization and lifestyle reinforcement. Specialist referral if refractory symptoms.

## 📚 Sources

1.  **Freeman R, Wieling W, Axelrod FB, et al.** Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clin Auton Res.* 2011;21(2):69-72. [PMID: 21431947](https://pubmed.ncbi.nlm.nih.gov/21431947/). \[Source for: orthostatic hypotension definition — SBP drop ≥20 or DBP drop ≥10 within 3 min of standing.\]
2.  **SPRINT Research Group.** A Randomized Trial of Intensive vs Standard BP Control. *N Engl J Med.* 2015;373(22):2103-2116. [PMID: 26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/). \[Source for: SPRINT orthostatic hypotension and falls data — falls HR 1.00 (no signal); orthostatic syncope SAE rate higher in intensive arm.\]
3.  **Whelton PK, et al.** 2017 ACC/AHA HTN Guideline. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/). \[Source for: target individualization in patients with orthostatic hypotension.\]
4.  **Juraschek SP, Daya N, Rawlings AM, et al.** Association of History of Dizziness and Long-term Adverse Outcomes With Early vs Later Orthostatic Hypotension Assessments. *JAMA Intern Med.* 2017;177(9):1316-1323. [PMID: 28738139](https://pubmed.ncbi.nlm.nih.gov/28738139/). \[Source for: orthostatic hypotension assessment timing — early (within 1 min) vs delayed measurement; ARIC cohort outcomes.\]

### 🎯 Key Learning Points

#### 🔄 Paradigm Shift

- Improved BP control reduces OH risk long-term
- Asymptomatic OH should not prevent intensive treatment
- Cardiovascular benefits outweigh theoretical risks

#### 🎯 Risk Stratification

- Focus on symptoms and falls risk, not just numbers
- Age and frailty influence treatment approach
- Individual assessment guides management decisions

#### ⚕️ Management Strategy

- Behavioral interventions as first-line therapy
- Medication optimization over discontinuation
- Gradual titration with close monitoring

#### 📊 Evidence-Based Care

- SPRINT trial supports intensive treatment safety
- Standardized measurement protocols essential
- Quality of life metrics guide decision-making


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/orthostatic-hypotension.html) · Markdown synchronized October 3, 2026.